Nortiva Bio Present New Clinical Data from its Development Pipeline and Broad Commercial Portfolio at IDWeek 2025
In the world of medicine, one of the biggest challenges is making sure patients take their medications consistently. Many treatments require daily dosing, which can be difficult for patients to maintain over long periods of time. Nortiva Bio is working to solve this problem by developing innovative drug delivery technology that allows medications to be taken far less frequently—potentially once a week or even longer.
Adverse Reactions
In the world of medicine, one of the biggest challenges is making sure patients take their medications consistently. Many treatments require daily dosing, which can be difficult for patients to maintain over long periods of time. Nortiva Bio is working to solve this problem by developing innovative drug delivery technology that allows medications to be taken far less frequently—potentially once a week or even longer.
Drug Interactions
Nortiva Bio is a clinical-stage biopharmaceutical company focused on creating long-acting oral therapies. The company is developing a proprietary platform called LYNX™, which enables medications to be delivered through a single oral dose that releases drugs slowly and steadily over an extended period of time. This approach is designed to maintain sustained, steady-state drug levels in the body, potentially for a week or longer after a single dose.
Use In Specific Populations
-
GERIATRIC POPULATION
Older adults often take multiple medications each day, which can make treatment plans difficult to follow. Nortiva Bio’s long-acting oral delivery technology may help simplify these regimens by reducing dosing frequency to once a week or longer. This could improve medication adherence and help maintain more consistent therapeutic drug levels in aging populations.
-
CHRONIC CONDITIONS
People living with chronic diseases such as diabetes, hypertension, or infectious diseases often require long-term daily medications. Missing doses can reduce treatment effectiveness and increase health risks over time. Nortiva Bio’s sustained-release oral dosage form may help improve adherence by delivering steady drug levels from a single weekly dose.
-
PATIENTS WHO STRUGGLE WITH MEDICAL ADHERENCE
Many patients find it difficult to remember to take medications every day. Forgetting doses can lead to inconsistent drug levels and reduced treatment effectiveness. A once-weekly oral dosage form could help simplify treatment routines and support better adherence.
-
PATIENTS WHO HAVE LIMITED HEALTH CARE
Some patients live in areas where regular pharmacy visits or frequent prescription refills are difficult. Long-acting oral therapies could reduce the need for frequent medication pickups or clinic visits. By extending the dosing interval, Nortiva Bio’s technology may help improve treatment continuity in underserved populations.
Sources
[1] WORLD HEALTH ORGANIZATION (WHO), MULTI-DRUG RESISTANT GONORRHOEA FACT SHEET, 22 OCTOBER 2025.; HTTPS://WWW.WHO.INT/NEWS-ROOM/FACT-SHEETS/DETAIL/MULTI-DRUG-RESISTANT-GONORRHOEA#:~:TEXT=KEY%20FACTS,AND%2C%20MORE%20RECENTLY%2C%20QUINOLONES.
[1] WORLD HEALTH ORGANIZATION (WHO), MULTI-DRUG RESISTANT GONORRHOEA FACT SHEET, 22 OCTOBER 2025.; HTTPS://WWW.WHO.INT/NEWS-ROOM/FACT-SHEETS/DETAIL/MULTI-DRUG-RESISTANT-GONORRHOEA#:~:TEXT=KEY%20FACTS,AND%2C%20MORE%20RECENTLY%2C%20QUINOLONES.